Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
Abivax (ABVX) announced the presentation of seven scientific abstracts focusing on obefazimod, its lead drug candidate for treating moderately to severely active ulcerative colitis (UC), at the upcoming European Crohn's and Colitis Organization's 20th Annual Congress in Berlin (February 19-22, 2025).
The presentations include one oral presentation on the efficacy and safety of dose de-escalation from 50mg to 25mg QD of obefazimod maintenance treatment, and six poster presentations covering various aspects including histologic outcomes, integrated safety summary, health-related quality of life, long-term efficacy and safety after dose de-escalation, treatment patterns, and synergistic reduction of inflammatory cytokines.
The presentations will feature research from prominent medical experts, including Prof. Silvio Danese, Prof. Séverine Vermeire, and Prof. Parambir S. Dulai, among others.
Abivax (ABVX) ha annunciato la presentazione di sette abstract scientifici incentrati su obefazimod, il suo principale candidato farmaco per il trattamento della colite ulcerosa (UC) moderatamente grave, al prossimo 20° Congresso Annuale dell'Organizzazione Europea per il Crohn e la Colite che si terrà a Berlino (dal 19 al 22 febbraio 2025).
Le presentazioni includeranno un intervento orale sull'efficacia e la sicurezza della riduzione della dose da 50 mg a 25 mg al giorno per il trattamento di mantenimento con obefazimod, insieme a sei presentazioni poster che coprono vari aspetti, tra cui risultati istologici, riassunto integrato di sicurezza, qualità della vita correlata alla salute, efficacia e sicurezza a lungo termine dopo la riduzione della dose, schemi di trattamento e riduzione sinergica delle citochine infiammatorie.
Le presentazioni presenteranno ricerche di esperti medici di spicco, tra cui il Prof. Silvio Danese, il Prof. Séverine Vermeire e il Prof. Parambir S. Dulai, tra gli altri.
Abivax (ABVX) anunció la presentación de siete resúmenes científicos centrados en obefazimod, su principal candidato a fármaco para tratar la colitis ulcerosa (UC) moderadamente a severamente activa, en el próximo 20º Congreso Anual de la Organización Europea de Crohn y Colitis que se llevará a cabo en Berlín (del 19 al 22 de febrero de 2025).
Las presentaciones incluirán una presentación oral sobre la eficacia y seguridad de la reducción de la dosis de 50 mg a 25 mg al día del tratamiento de mantenimiento con obefazimod, así como seis presentaciones en cartel que abarcarán diversos aspectos, incluyendo resultados histológicos, resumen integrado de seguridad, calidad de vida relacionada con la salud, eficacia y seguridad a largo plazo tras la reducción de la dosis, patrones de tratamiento y reducción sinérgica de citoquinas inflamatorias.
Las presentaciones contarán con investigaciones de destacados expertos médicos, incluyendo al Prof. Silvio Danese, la Prof. Séverine Vermeire y el Prof. Parambir S. Dulai, entre otros.
Abivax (ABVX)는 다가오는 유럽 크론병 및 콜라이티스 조직의 제20회 연례 총회에서 중등도에서 중증 활동성 궤양성 대장염(UC) 치료를 위한 주요 약물 후보인 오베파지모드에 관한 7개의 과학적 초록을 발표할 것이라고 발표했습니다. (2025년 2월 19일-22일, 베를린).
발표에는 오베파지모드 유지 치료의 복용량을 50mg에서 25mg으로 줄이는 것에 대한 효과와 안전성을 다룬 구두 발표가 포함되며, 조직학적 결과, 통합 안전성 요약, 건강 관련 삶의 질, 복용량 감소 후 장기 효과 및 안전성, 치료 패턴 및 염증 사이토카인의 시너지 감소 등 다양한 측면을 다룬 6개의 포스터 발표가 포함됩니다.
이번 발표는 실비오 다네세 교수, 세베린 베르메르 교수, 파람비르 S. 둘라이 교수 등 저명한 의료 전문가들의 연구 결과를 특징으로 합니다.
Abivax (ABVX) a annoncé la présentation de sept résumés scientifiques portant sur obefazimod, son principal candidat médicament pour le traitement de la colite ulcéreuse (UC) modérément à sévèrement active, lors du prochain 20e Congrès Annuel de l'Organisation Européenne de Crohn et Colite à Berlin (du 19 au 22 février 2025).
Les présentations comprendront une présentation orale sur l'efficacité et la sécurité de la réduction de dose de 50 mg à 25 mg par jour du traitement d'entretien avec obefazimod, ainsi que six présentations sous forme d'affiches abordant divers aspects, y compris les résultats histologiques, le résumé intégré de sécurité, la qualité de vie liée à la santé, l'efficacité et la sécurité à long terme après réduction de dosage, les schémas de traitement et la réduction synergique des cytokines inflammatoires.
Les présentations mettront en avant des recherches d'experts médicaux de renom, notamment le Prof. Silvio Danese, le Prof. Séverine Vermeire et le Prof. Parambir S. Dulai, entre autres.
Abivax (ABVX) gab die Präsentation von sieben wissenschaftlichen Abstracts bekannt, die sich auf obefazimod konzentrieren, das Hauptmedikamentenkandidaten zur Behandlung von moderat bis schwer aktiver Colitis ulcerosa (UC), auf dem bevorstehenden 20. Jahreskongress der Europäischen Crohn- und Colitis-Vereinigung in Berlin (19. bis 22. Februar 2025).
Zu den Präsentationen gehört ein mündlicher Vortrag über die Wirksamkeit und Sicherheit der Dosisreduktion von 50 mg auf 25 mg täglich bei der Erhaltungsbehandlung mit obefazimod sowie sechs Posterpräsentationen, die verschiedene Aspekte wie histologische Ergebnisse, integrierte Sicherheitszusammenfassung, gesundheitsbezogene Lebensqualität, Langzeitwirksamkeit und -sicherheit nach Dosisreduktion, Behandlungsmuster und synergistische Reduktion von entzündlichen Zytokinen abdecken.
Die Präsentationen beinhalten Forschung von prominenten medizinischen Experten, darunter Prof. Silvio Danese, Prof. Séverine Vermeire und Prof. Parambir S. Dulai, neben anderen.
- Multiple aspects of obefazimod's clinical development will be presented at a major industry conference
- Research includes long-term efficacy and safety data up to 6 years of treatment
- Presentations feature research from prominent medical experts in the field
- None.
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational, orally administered, once-daily small molecule] in clinical development for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at The European Crohn’s and Colitis Organization’s (ECCO’s) 20th Annual Congress as part of scientific exchange, taking place February 19-22, 2025, in Berlin, Germany.
“With 7 abstracts accepted for presentation at ECCO 2025, we look forward to our continued exchange with the inflammatory bowel disease community around the emerging clinical profile of obefazimod,” said Fabio Cataldi, MD, Chief Medical Officer of Abivax.
For more information, see congress details on the ECCO website, and visit the Abivax booth at the ECCO exhibitor hall (booth #30).
Obefazimod data to be presented:
| Presentation Title | Session | Presenter | Presentation/ Session Number | Session Hall | Date and Time (EDT) |
| Oral Presentation | |||||
| "Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD" | Digital Oral Presentation Session 6 | Prof. Silvio Danese, MD, PhD Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital | Clinical Trials III | Hall A7 | Friday, February 21, 2025 8:42am to 8:48am |
| Poster Presentations | |||||
| "Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study" | Guided Poster Session | Fernando Magro, MD, PhD President-Elect of ECCO. Head of the Department of Clinical Pharmacology and Professor of Pharmacology and Therapeutics at University Hospital São João in Porto, Portugal | Poster number: P0636 | Hall 2.2 | Friday, February 21, 2025 12:40pm to 1:40pm |
| "Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis" | Guided Poster Session | Prof. Séverine Vermeire, MD, PhD Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC | Poster number: P0813 | Hall 2.2 | Friday, February 21, 2025 12:40pm to 1:40pm |
| "Health-related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2 open-label maintenance study" | Guided Poster Session | Jennifer Fine, ScD Head of HEOR, Abivax S. A | Poster number: P0840 | Hall 2.2 | Friday, February 21, 2025 12:40pm to 1:40pm |
| "Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mg" | Guided Poster Session | Prof. Silvio Danese, MD, PhD Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital | Hall 2.2 | Friday, February 21, 2025 12:40pm to 1:40pm | |
| "Long-term treatment patterns, dose escalation, and steroid use among patients with moderate-to-severe ulcerative colitis using advanced therapies: 3 years of continuous follow-up using IQVIA PharMetrics Plus database" | Guided Poster Session | Prof. Parambir S. Dulai, M.D. Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois | Hall 2.2 | Friday, February 21, 2025 12:40pm to 1:40pm | |
| "Synergistic reduction of inflammatory cytokines with obefazimod and etrasimod in combination treatment vs. either monotherapy in a mouse model of inflammatory bowel disease" | Guided Poster Session | Didier Scherrer, PhD Chief Scientific Officer Abivax S.A. | Hall 2.2 | Friday, February 21, 2025 12:40pm to 1:40pm | |
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878
FAQ
What are the key findings being presented about ABVX's obefazimod at ECCO 2025?
When and where will ABVX present its obefazimod data at ECCO 2025?
What is the current development stage of ABVX's obefazimod for ulcerative colitis?
What dosing information will be presented for ABVX's obefazimod at ECCO 2025?
